

3914 Del Amo Blvd SUITE 901 TORRANCE, CA 90503 www.celprogen.com Phone: 310 542 8822 Fax: 310 542 8028 Email: info@celprogen.com stemcells@celprogen.com

DATA SHEET

Human Prostate Cancer Stem Cell Freezing Media

Catalog number: M36103-30-FM

Description: Human Prostate Cancer Stem Cell Freezing Media. This media is

available in ready to use format. Media is optimized for freezing Human Prostate Cancer Stem Cells. Each lot is qualified to support Human Prostate Cancer Stem Cell freezing and thawing for Cell storage.

Storage Conditions: -20^oC

Tissue culture: The Human Prostate Cancer Stem Cell Freezing Media was tested and

optimized with Human Prostate Cancer Stem Cell storage and recovery. The Human Prostate Cancer Stem Cell was grown on Celprogen's Human Prostate Cancer Stem Cell Extra-cellular Matrix pre-coated flasks and Media. Ideally the cells should be frozen down when they are in their growth phase. Prior to freezing the cells the media should be changed 24 hours before. Freezing cells: a slow and reproducible cooling rate is very important to ensure good recovery of cultures. A decrease of -1 to

-3 °C / minute is recommended for Celprogen's cell culture.

Product Orders: Before submitting an order you will be asked to read and accept the

terms and conditions of Celprogen's Material Transfer Agreement.

Permits/Forms: In addition to the MTA mentioned above, other CELPROGEN and/or

regulatory permits may be required for the transfer of this CELPROGEN material. Anyone purchasing CELPROGEN material is ultimately

responsible for obtaining the permits for their country of origin.

Notices &

Disclaimers: CELPROGEN products are intended for laboratory research purposes

only. They are not intended for use in humans. The product, Human Prostate Cancer Stem Cell Freezing Media, which contains 10% DMSO, is established and manufactured by CELPROGEN Inc., and is for Research Use Only. This product is not for re-sale and may not be transferred to a third party prior to written request and approval by

CELPROGEN Inc.